A New Deal for Cancer
26,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 2-4 Wochen
payback
13 °P sammeln
  • Gebundenes Buch

"With a chapter by Siddartha Mukherjee"--Cover.

Andere Kunden interessierten sich auch für
Produktbeschreibung
"With a chapter by Siddartha Mukherjee"--Cover.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Abbe R. Gluck is  is the Alfred M. Rankin Professor of Law, the founding faculty director of the Solomon Center for Health Law and Policy at Yale Law School, professor of internal medicine at Yale School of Medicine and the faculty director of the Yale Medical-Legal Partnership. She is also a Professor in the Institution for Social and Policy Studies at Yale. Gluck is an expert on Congress, federalism, litigation, and health law and is the author of more than 60 articles in law, health and mainstream publications, as well as the author of a leading legislation casebook. After graduation from Yale Law School, Gluck clerked for U.S. Supreme Court Justice Ruth Bader Ginsburg and worked on the senior staffs in the administrations of NYC Mayor Michael Bloomberg and NJ Governor Jon Corzine. Gluck filed influential amicus briefs in all of the major ACA challenges.     Charles S. Fuchs MD, MPH is Senior Vice President and Global Head of Product Development for Oncology and Hematology at Genentech and Roche, former Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital, and Adjunct Professor of Medicine at Yale Cancer Center. Dr. Fuchs has spent his career advancing and enabling great science toward improving the lives of people with cancer. An internationally recognized expert in cancer care, treatment, and prevention, he was previously Professor of Medicine at Harvard Medical School and Chief of the Gastrointestinal Oncology Division and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute. Dr. Fuchs’ research and laboratory include work in molecular epidemiology, translational science, and drug development with over 700 publications and multiple FDA approvals of new cancer therapies.